BillionToOne, Inc. BLLN

Company Overview

BillionToOne, Inc. is a privately held molecular diagnostics company operating in the biotechnology and clinical diagnostics industries. The company develops and commercializes advanced DNA-based diagnostic tests that leverage its proprietary quantitative molecular counting technology to improve accuracy in detecting genetic variations. Its core focus areas include reproductive health, oncology, and genetic disease screening, serving clinicians, laboratories, and healthcare systems.

The company’s primary revenue drivers are its commercially available diagnostic tests, particularly non-invasive prenatal screening (NIPS) products and oncology liquid biopsy assays. BillionToOne, Inc. positions itself through a technology platform designed to overcome limitations of traditional next-generation sequencing by accurately counting individual DNA molecules, which it markets as a key differentiator in sensitivity and specificity. Founded in 2016, the company evolved from a technology-focused startup into a commercial-stage diagnostics provider, expanding its test menu and clinical adoption through regulatory progress and peer-reviewed validation.